icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
bqm9XKfd2bFP8afR
Listen
